SeaStar Medical's SCD Therapy Pioneer Honored as University of Michigan Innovator of the Year
Event summary
- H. David Humes, M.D., developer of SeaStar Medical's Selective Cytopheretic Device (SCD) therapy, received the University of Michigan 2026 Distinguished University Innovator of the Year award on September 24, 2026.
- SCD therapy, commercialized as QUELIMMUNE®, is the first and only FDA-approved treatment for critically ill pediatric patients with acute kidney injury (AKI) and sepsis.
- QUELIMMUNE demonstrated a 50% reduction in patient mortality at 60 days compared to the standard of care in clinical trials.
- SeaStar Medical is conducting the NEUTRALIZE-AKI clinical trial to evaluate the SCD therapy in adult patients with life-threatening AKI.
The big picture
The recognition of Dr. Humes underscores the transformative potential of SCD therapy in treating hyperinflammation in critically ill patients. SeaStar Medical's focus on expanding the therapy's applications beyond pediatric AKI positions it at the forefront of innovative treatments for organ failure. The company's ability to navigate regulatory pathways and secure reimbursement will be critical in scaling its commercial impact.
What we're watching
- Clinical Trial Progress
- The outcome of the NEUTRALIZE-AKI pivotal trial will determine the efficacy of SCD therapy in adult patients with AKI, potentially expanding the market for SeaStar Medical's products.
- Regulatory Approvals
- The pace at which SeaStar Medical secures additional FDA approvals for SCD therapy in other indications will impact its commercialization strategy and revenue growth.
- Market Adoption
- How quickly QUELIMMUNE is adopted by the pediatric critical care community will influence SeaStar Medical's ability to achieve commercial success and sustain profitability.
Related topics